Regen BioPharma Files 8-K: Material Agreement & Equity Sales
Ticker: RGBPP · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1589150
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
Regen BioPharma filed an 8-K on Oct 2, 2025, detailing a material agreement and equity sales.
AI Summary
On October 2, 2025, Regen BioPharma Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing indicates significant corporate activity, including a material definitive agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Regen BioPharma Inc. (company) — Issuer of the 8-K filing
- October 2, 2025 (date) — Earliest event reported date
- Nevada (jurisdiction) — State of incorporation
- 45-5192997 (ein) — IRS Employer Identification Number
- 333-191725 (commission_file_number) — SEC File Number
- 4700 Spring Street, St 304, La Mesa, California 91942 (address) — Principal Executive Offices
- 619-722-5505 (phone_number) — Issuer's telephone number
FAQ
What is the primary purpose of this Form 8-K filing for Regen BioPharma Inc.?
The primary purpose is to report on the entry into a material definitive agreement, unregistered sales of equity securities, and other events, as required by Section 13 or 15(d) of the Securities Exchange Act of 1934.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on October 2, 2025.
In which U.S. state is Regen BioPharma Inc. incorporated?
Regen BioPharma Inc. is incorporated in Nevada.
What is the principal executive office address for Regen BioPharma Inc.?
The principal executive office address is 4700 Spring Street, St 304, La Mesa, California 91942.
What specific items are being reported under the Form 8-K filing?
The filing reports on Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 5.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits).
Filing Stats: 1,092 words · 4 min read · ~4 pages · Grade level 12.2 · Accepted 2025-10-03 06:06:02
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex10-1.htm (EX-10.1) — 31KB
- ex10-2.htm (EX-10.2) — 12KB
- 0001493152-25-016767.txt ( ) — 257KB
- rgbp-20251002.xsd (EX-101.SCH) — 3KB
- rgbp-20251002_lab.xml (EX-101.LAB) — 33KB
- rgbp-20251002_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01 by reference
Item 1.01 by reference. On October 2, 2025 the Company entered into an agreement with David Koos, the Company's Chairman and Chief Executive Officer ("Koos Agreement"). Pursuant to the Koos Agreement David Koos was paid twenty million newly issued common shares of the Company ("Koos Compensation Shares") subject to a vesting schedule. The Company has issued these shares to Davis Koos as consideration for services to be rendered by Koos in connection with a planned Phase I Clinical Trial of HemaXellerate . The Koos Compensation Shares may not be sold, transferred, assigned, pledged or otherwise encumbered or disposed of by David Koos (" Transfer Restriction") except as follows: All Koos Compensation Shares shall vest upon successful completion of planned Phase I Clinical Trial of HemaXellerate, such Clinical Trial having been conducted with the assistance of the Consultant pursuant to the terms and conditions of this Agreement. The foregoing description of the abovementioned Koos Agreement is not complete and is qualified in its entirety by reference to the text of the abovementioned Koos Agreement which is attached to this Current Report on Form 8-K as Exhibit 10.2 and incorporated in this Item 1.01 by reference. HemaXellarate , a stem cell derived therapy being developed by the Company, is a cellular composition of autologous stromal vascular fraction derived from adipose tissue. The Company intends to initiate a Phase I clinical trial assessing HemaXellerate in patients with drug-refractory aplastic anemia. The Phase I clinical trial is intended to determine safety and potential efficacy of intravenously administered autologous stromal vascular fraction (SVF) cells in patients with severe, immune suppressive refractory aplastic anemia with the primary endpoints of safety and feasibility and secondary endpoints of efficacy as determined by patients having complete response, partial response or relapse. 3.02 Unregistered Sales of Equity Securities On O